Avonex (recombinant IFN-β-1a) / Biogen  >>  Phase 3
Welcome,         Profile    Billing    Logout  

18 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Avonex (recombinant IFN-β-1a) / Biogen
NCT00292266: A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

Completed
3
677
US
Rebif®, Avonex®
EMD Serono, Merck Serono International SA
Multiple Sclerosis, Relapsing-Remitting
06/02
06/02
NCT00030966: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Completed
3
1200
US, Europe, RoW
Natalizumab, Tysabri, Placebo
Biogen, Elan Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
04/05
12/05
NCT00242268: A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Unknown status
3
30
US
Simvastatin
Alabama Neurology Associates, PC, Biogen
Relapsing Remitting Multiple Sclerosis
 
 
NCT00915577: Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Completed
3
74
US
Interferon beta-1a, Avonex, Single-use autoinjector
Biogen
Multiple Sclerosis
04/06
04/06
BRAVO, NCT00605215 / 2007-005450-23: Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Checkmark AAN 2016: ALLEGRO & BRAVO
Mar 2016 - Mar 2016: AAN 2016: ALLEGRO & BRAVO
Checkmark Pooled data from extensions of ALLEGRO and BRAVO trials for multiple sclerosis
Jun 2015 - Jun 2015: Pooled data from extensions of ALLEGRO and BRAVO trials for multiple sclerosis
Checkmark ACTRIMS-ECTRIMS 2014: MS (BRAVO)
More
Completed
3
1331
Europe, US, RoW
Laquinimod, Placebo, Avonex®, Interferon β-1a
Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
06/11
06/11
TRANSFORMS, NCT00340834 / 2006-000704-17: Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Checkmark TRANSFORMS
Oct 2014 - Oct 2014: TRANSFORMS
Checkmark TRANSFORMS
May 2014 - May 2014: TRANSFORMS
Checkmark AAN 2014: Multiple sclerosis (TRANSFORMS & FREEDOMS & FREEDOMS II)
More
Completed
3
1292
US, Canada, Europe, RoW
Fingolimod 1.25 mg, FTY720, Fingolimod 0.5 mg, Interferon β-1a 30 µg
Novartis
Multiple Sclerosis
07/11
07/11
NCT01064401 / 2009-012500-11: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Checkmark CMSC 2016
Jun 2016 - Jun 2016: CMSC 2016
Checkmark From SELECT and DECIDE trials in MS
Jun 2016 - Jun 2016: From SELECT and DECIDE trials in MS
Checkmark DECIDE; SELECT trilogy
More
Completed
3
1841
US, Canada, Europe, RoW
BIIB019 (Daclizumab High Yield Process), DAC HYP, Interferon beta-1a Placebo, Interferon beta-1a, Avonex, IFN β-1a, Daclizumab High Yield Process Placebo
Biogen, AbbVie
Relapsing-Remitting Multiple Sclerosis
03/14
07/14
LIBRETTO, NCT01975298 / 2013-002082-19: A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Withdrawn
3
0
NA
Laquinimod, TV-5600, Avonex®, Interferon β1A
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
03/14
03/14
2013-003126-83: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.

Completed
3
1176
Europe, RoW
Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Film-coated tablet, Solution for infusion in pre-filled syringe, Avonex
Merck KGaA, Merck KGaA
Relapsing multiple sclerosis, Multiple sclerosis, Diseases [C] - Nervous System Diseases [C10]
 
 
2013-002351-15: Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.

 
3
88
Europe
Avonex, MSC2430913A or ONO-4641 (to be used as synonyms), Avonex, Avonex
Merck KGaA, Merck KGaA
Relapsing remitting multiple sclerosis
 
08/14
SUNBEAM, NCT02294058 / 2014-002320-27: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Completed
3
1346
Europe, Canada, US, RoW
Ozanimod, RPC1063, Zeposia®, Interferon beta-1a, Avonex®, IFN β-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Celgene
Multiple Sclerosis
12/16
12/16
Radiance, NCT02047734 / 2012-002714-40: Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Completed
3
1320
Europe, Canada, US, RoW
Ozanimod, RPC1063, Zeposia®, Ozanimod placebo, Interferon beta-1a, Avonex, Interferon beta-1a placebo
Celgene, Receptos, Inc., Celgene International II Sàrl (CIS II)
Relapsing Multiple Sclerosis
03/17
04/17
EVOLUTION MS1, NCT04032158 / 2018-004701-11: Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

Terminated
3
3
Europe, US
Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
04/20
04/20
EVOLUTION MS2, NCT04032171 / 2018-004700-19: Study of Evobrutinib in Participants With RMS

Terminated
3
1
Europe, US
Evobrutinib, M2951, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Relapsing-remitting Multiple Sclerosis
05/20
05/20
CONNECT, NCT02283853 / 2013-002318-11: Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting
3
156
Europe, Canada, US, RoW
dimethyl fumarate, BG00012, Tecfidera, Interferon β-1a, Avonex
Biogen
Relapsing-Remitting Multiple Sclerosis
09/25
09/25
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
07/24
05/27
NCT00223301: Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

Completed
2/3
24
US
Mycophenolate Mofetil (cellcept)
University of Texas Southwestern Medical Center, Roche Pharma AG, Biogen
Multiple Sclerosis
03/07
03/07
NCT02744222: Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Completed
2/3
399
RoW
BCD-054 180 mcg, pegylated interferon beta-1a, Avonex®, interferon beta-1a, BCD-054 240 mcg, Placebo
Biocad
Multiple Sclerosis, Relapsing-Remitting
11/18
07/20

Download Options